StockData
Inhibrx Biosciences, Inc. logo

Inhibrx Biosciences, Inc. (INBX) stock

INBXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$83.30−4.45 (-5.07%)

Close on Nov 13, 2026Market cap $1.23BP/E –Yield –

Inhibrx Biosciences profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Inhibrx Biosciences's profit margin for the twelve months ending Dec 31, 2025 was -10773.5%. For fiscal 2025 it was -10773.5%, against 843786.0% the year before. The highest annual figure on record is 843786.0% in fiscal 2024.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-10773.5%−854559.5
FY2024Dec 31, 2024843786.0%+857194.9
FY2023Dec 31, 2023-13408.9%−6783.7
FY2022Dec 31, 2022-6625.3%−5494.5
FY2021Dec 31, 2021-1130.8%−540.1
FY2020Dec 31, 2020-590.7%−201.6
FY2019Dec 31, 2019-389.1%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 2026-1936.6%+3791.9
Q2 FY2025Jun 30, 2025-2204.2%+41316.0
Q4 FY2024Dec 31, 2024-47865.0%+108975.0
Q2 FY2024Jun 30, 20241858011.0%+2145752.2
Q4 FY2023Dec 31, 2023-5728.5%+9204.0
Q3 FY2023Sep 30, 2023-43520.2%−30813.3
Q2 FY2023Jun 30, 2023-156840.0%−151533.1
Q1 FY2023Mar 31, 2023-287741.2%−284376.9
Q4 FY2022Dec 31, 2022-14932.5%−14190.6
Q3 FY2022Sep 30, 2022-12706.8%−11894.0
Q2 FY2022Jun 30, 2022-5306.9%−3136.0
Q1 FY2022Mar 31, 2022-3364.3%−1194.5
Q4 FY2021Dec 31, 2021-741.9%−106.1
Q3 FY2021Sep 30, 2021-812.8%−465.4
Q2 FY2021Jun 30, 2021-2170.9%−1635.2
Q1 FY2021Mar 31, 2021-2169.7%+134.5
Q4 FY2020Dec 31, 2020-635.8%+5563.8
Q3 FY2020Sep 30, 2020-347.3%+1306.7
Q2 FY2020Jun 30, 2020-535.6%–
Q1 FY2020Mar 31, 2020-2304.2%–
Q4 FY2019Dec 31, 2019-6199.6%–
Q3 FY2019Sep 30, 2019-1654.1%–

More Inhibrx Biosciences figures

See a number that looks wrong?